Thyroid hormones (THs) are important effectors of cell growth, development, tissue differentiation, and metabolism. Disturbance of these and other biological processes often results in neoplastic transformation and cancer development (20, 51) . The recent cloning and characterization of TH-specific nuclear receptors (TRs) have greatly increased knowledge of the mechanism(s) by which THs control gene expression. TRs belong to a large family of regulatory proteins that include receptors for steroid hormones and for vitamin D and vitamin A derivatives (3, 13, 23) . These receptors function as ligand-activated transcription factors that bind to their cognate DNA sequences near promoters of responsive genes. In the absence of ligand, TRs bind thyronine (T3)-responsive elements (T3RE) and function as transcriptional repressors or silencers (9, 22, 55) . This is in contrast to the larger glucocorticoid receptor (GR) protein, which is predominantly located in the cell cytoplasm in the absence of hormone and has not yet been shown to possess any ligand-independent regulatory functions in vivo (3, 69) .
The TRs are encoded by two different genes, TRa and TR,, from which multiple isoforms can be generated (4, 30, 54, 65, 67). The two TRPi isoforms, TR,1 and TR,B2, differ in their amino termini but are both ligand-dependent transcriptional enhancers. At least three distinct isoforms have been isolated from the human and rat TRa genes (4, 36, 38, 44, 45, 47) . However, only one of these isoforms, TRal, is a ligand-dependent activator of transcription, while the other isoforms are receptorlike molecules that do not bind TH and are not transcriptional activators. Although these isoforms appear to have repressor activities (25, 35, 38) , their biological functions are not well understood.
The role of TH in cancer development and cellular transformation has been controversial. Positive effects were observed in studies on mammary cancers (62) (63) (64) 66) , while * Corresponding author.
other data suggested an enhancing effect of TH on cell transformation (24, 40, 41) . However, the identification of TRa as a cellular counterpart of the viral erbA gene implicates its potential role in tumor development (30, 54, 67) . v-erbA cooperates with a number of tyrosine-kinase-encoding oncogenes and ras-like oncogenes in the process of cellular transformation (17, 32, 33) . v-erbA potentiates the transforming activity of v-erbB (a truncated epidermal growth factor receptor) in chicken embryo fibroblast (18) and is required for v-erbB, ras, and src oncogenes to transform erythrocyte progenitor cells (17, 32, 33) . The role of v-erbA in the cooperation with these oncogenes during cell transformation is probably due to its ability to interfere with the c-erbA-regulated differentiation program of these cells (17, 32, 33, 72) . Recent studies suggest that v-erbA might have arisen from a dominant negative mutation of c-erbA, resulting in the loss of the ligand-dependent transcriptional activation function but maintaining its repressor activity (9, 55) . It is possible that the lack of ligand-dependent function, in combination with the constitutive repressor activity of v-erbA, plays a crucial part in the events leading to cell transformation. This would also suggest that the normal cellular counterpart of v-erbA might participate in the control of cellular transformation and possibly interfere with the action of certain oncogenes, including v-erbB, ras, and src. These oncogenes as well as many growth factors and the tumor promoter tetradecanoyl phorbol acetate (TPA) activate c-Jun or c-Fos, components of the transcription factor AP-1, through the protein kinase C pathway (reviewed in references 8, 34, and 53). AP-1 binds to specific DNA sequences either as c-Jun homodimers or c-Jun/c-Fos heterodimers. Here we report evidence for a regulatory pathway by which TRs can directly interfere with the signal transduction pathway induced by the tumor promoter TPA and counteract AP-1 activity. The interference appears to be due to the direct interaction of TRs with AP-1, the activation product of TPA.
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MATERIALS AND METHODS
Recombinant plasmids. The T3RE2-tk-CAT construct was prepared as described previously (22, 73) . Briefly, two copies of the synthetic palindromic sequence (TCAGGT CATGACCTGA) were inserted into the BamHI site of pBL-CAT2 by using BglII linkers. The AP-1 site present in the vector was deleted by DraII and NdeI digestion, filling in, and religation. The -73Col-CAT and pfos-CAT reporter constructs were described by Angel et al. (1) and Schonthal et al. (56) , respectively. Coding sequences for TRa and TR13 receptor were inserted into the multiple cloning sites of the eukaryotic expression vector pECE or pBluescript (Stratagene) as described previously (22, 73) . To obtain the deletion mutants of TR13, existing restriction sites (BsmI and SmaI) in the TR,B cDNA clone were used to obtain the TR13 truncated mutants, which were cloned into pECE to generate ATR13l and ATR12 expression vectors. The c-jun and c-fos expression vectors have been described elsewhere (70) .
Proteins and antibodies. The cDNAs for TRa, TR13, c-Fos and c-Jun were cloned into pBluescript (Stratagene) or a comparable vector (pGem4z; Promega). They were transcribed by using the T7, T3, or SP6 RNA polymerase and translated in rabbit reticulocyte lysate (Promega) as described previously (52, 73 Tissue culture, transient transfection, and CAT assay. HeLa and CV-1 cells were grown in DME medium supplemented with 10% calf serum. GC cells were maintained in DME medium with 5% horse serum and 2.5% fetal calf serum. A modified calcium phosphate precipitation procedure was used for transient transfection as described previously (52) . Typically, 2 ,ug of reporter construct, 3 ,ug of 1-galactosidase (13-gal) expression vector (pCH11O; Pharmacia), and various expression vectors for receptors, c-Jun, or c-Fos were mixed with carrier DNA (pBluescript) to 20 ,ug of total DNA per plate. After transfection, cells were grown in DME medium supplemented with the appropriate percentage of serum and treated with TH or TPA as described in the figure legends. 1-Gal activity was measured as described elsewhere (52) . CAT activity was determined by using 3H-acetyl coenzyme A as the substrate (52) . To normalize for transfection efficiency, CAT activities were corrected for 1-gal activity.
RESULTS
c-jun and c-fos inhibit TR activities. TRs and the nuclear proto-oncogenes fos and jun are important mediators of cell growth and differentiation. To study a possible link between the proto-oncogenes and TR activities, we investigated whether c-jun and c-fos expression could affect TR activity. Transfection of c-jun and c-fos expression vectors into CV-1 cells had no effect on the basal level activity of a TRresponsive reporter gene (T3RE2-tk-CAT). However, when c-jun or c-fos expression vectors were cotransfected together with TRa or TR1, they strongly inhibited the T3-induced activity of the reporter gene (Fig. 1 ). The degree of inhibition was dependent on the amount of c-jun or c-fos expression vector used. However, a slight enhancement of TR13 activity was consistently observed at low c-jun concentrations, while c-fos was an efficient inhibitor even at low concentrations. In addition, a clear increase in repression of were plated at 1.5 x 106 to 2.0 x 106 per dish 16 to 24 h prior to transfection in DME medium supplemented with 10% fetal calf serum. A modified calcium phosphate precipitation procedure was used for transient transfection as described previously (52) . Two micrograms of reporter construct T3RE2-tk-CAT (4, 16), 3 ±Lg of ,8-gal expression vector (pCH110; Pharmacia), 3 ,ug of TRa or TRI expression vector (4) , and the indicated amounts c-fos and c-jun expression vectors (70) were mixed with carrier DNA (Bluescript) to 20 ,ug of total DNA per plate. Cells were grown in the absence or presence of 10-7 M T3. 1-Gal was measured as described previously (52) . CAT activity was determined by using 3H-acetyl coenzyme A as the substrate (52 TR,B activity was observed when c-jun and c-fos were transfected together (Fig. 1B) .
TR,I inhibits induction of the c-fos promoter. The ability of c-jun and c-fos to ipterfere with TR-mediated TH induction led us to question whether TRs can also influence protooncogene activity. As one test system, a c-fos promoter reporter construct (pfos-CAT) (56) was chosen. The c-fos promoter can be activated by the tumor promoter TPA (5, 14, 15, 19, 61) , which activates endogenous AP-1 activity via protein kinase C. We therefore investigated whether TRs would also inhibit TPA-inducedfos promoter activity. When pfos-CAT was cotransfected into CV-1 cells together with a TR,B expression vector, we observed a strong reduction of TPA-induced Fos-CAT activity by coexpression of TR,B. This inhibition was T3 dependent (Fig. 2) . Cotransfection of After transfection, cells were grown in 0.5% fetal calf serum with or without TPA (100 ng/ml) for 24 h before harvesting.
a TRao expression vector also led to a reduction of Fos-CAT activity in the presence of T3. However, TRa was consistently a less effective repressor than TR,B, despite being approximately equally efficient in transcriptional activation (73) . The empty expression vector (pECE) had no effect (Fig. 2) . Somewhat surprisingly, a retinoic acid receptor (RAR,B) showed no repressing activity in CV-1 cells in the presence of retinoic acid, while we consistently observed a slight enhancing effect of RAR,B on Fos-CAT in the absence of ligand (Fig. 2) . We have, however, found that RAR1 is a potent TPA response inhibitor in HeLa cells (71) , indicating that cell-type-specific factors may modulate the anti-AP-1 activities of receptors. Thus, TRs can negatively regulate the induction of the c-fos promoter by TPA. TRs repress AP-1 site-dependent gene activation. The Fos promoter contains a serum response element and an AP-1 site, which both control its activity (5, 14, 15, 19, 50, 61) . To investigate the effect of TR on gene activation by TPA in a simpler model system, expression vectors for TRs were cotransfected into HeLa and CV-1 cells along with a collagenase promoter-reporter construct (-73Col-CAT). This collagenase promoter fragment lacks a serum response element but carries a TPA-responsive element (1, 54) that can be activated via the protein kinase C pathway by AP-1, resulting in a strong induction of the reporter gene in the presence of TPA (Fig. 3A) . Deletion of the AP-1 site leads to a loss of the TPA response (56) . In the absence of T3, expression of TRax or TR1 did not negatively interfere with TPA-induced activity of the reporter gene. However, the addition of T3 to the culture medium led to a drastic decrease of the TPA-induced CAT activity (Fig. 3A) . Inhibition of the TPA-induced reporter gene activity correlated positively with the concentration of the receptor expression vector used (Fig. 3A) .
The studies described above suggested that the inhibition of TPA activity by TRs may be mediated by the interaction of TRs with c-Jun and c-Fos, the constituents of AP-1. We therefore questioned whether the activities of c-Jun and c-Fos could be directly inhibited by TRs. In Fig. 3B (10-' M) . CAT assays were performed as descri in the presence of hormone. These results suggest that the inhibition of c-Jun and c-Fos activity is most likely to account for the repressive effects of TRs on TPA activity. This repressive effect was observed only in the presence hormone. Half-maximal repression was observed at 10-9 M T3. Thyroxine (T4) could also stimulate the anti-AP-1 activity of TRs, but a more than 10-fold-higher concentration was required. Similar inhibitory effects were observed on -73Col-CAT activity induced by c-Jun alone (data not shown). Reverse T3 (a weak agonist) showed no effect (Fig.  3C) . Cotransfection of an empty expression vector (pECE) together with different ligands also had no effect on c-Jun/c-+ Fos activity (data not shown). Thus, the activity of the tumor promoter TPA, c-Jun, and c-Fos, all of which function + through the AP-1 site in the -73Col-CAT construct, can be RJ3 antagonized by TR expression in the presence of active THs.
Mutual endogenous AP-1/TR antagonism in GC cells. The mutual antagonism observed between AP-1 and TR activities is reminiscent of the mutual antagonism observed between AP-1 and GRs (11, 31, 42, 47, 70) and may suggest direct interaction between nuclear receptors and Jun and/or Fos proteins. However, one important question that remains to be answered is whether this mutual antagonism can indeed function at physiological concentrations of both transcription factors. We examined TPA-TR antagonism in GC cells. These pituitary-derived cells showed a strong T3-dependent induction of the T3RE2-CAT reporter in the absence of cotransfected TR (Fig. 4A) . In addition, TPA led to a marked induction of the Col-CAT reporter in these cells (Fig. 4B) . At >+ the same time, TPA also inhibited T3-induced reporter activity (Fig. 4A) . Inhibition of T3 activity was also observed 3 3 by cotransfection of either c-jun or c-fos expression vectors or both. Conversely, T3 was able to markedly inhibit activation of the Col-CAT reporter by TPA in a concentrationdependent manner, while no significant T3 effect was observed on the basal level activity of this reporter. Our data thus clearly demonstrate that endogenous AP-1 and TR activities can inhibit each other in the same cell type.
A functional ligand/activation domain is necessary for TRI3-TPA antagonism. To delineate the regions of TRs that are necessary for the anti-AP-1 activity, a series of TR, deletion mutants was constructed; Fig. 5A depicts two of these mutants. The mutants were analyzed for their anti-AP-1 activity. Deletion of only 17 amino acids from the carboxy terminus of TRO (ATRP1) resulted in a loss of anti-AP-1 activity (Fig. 5B) . Deletion of larger regions of the carboxy terminus did not revert the loss of anti-AP-1 activities. In all cases, loss of AP-1 antagonism was coupled with loss of ligand-dependent gene induction activity (Fig. SC) .
The loss of anti-AP-1 activity observed with these TR, deletion mutants could be due to reduced expression levels of the mutant proteins. To compare the levels of mutant and wild-type receptor expression, receptor derivatives that carried an eight-amino-acid immunogenic sequence (Flag) at the :tivamino-terminal end were analyzed (Fig. 6A to E) . Expres- GC cells were grown in DME medium supplemented with 5% horse serum and 2.5% fetal calf serum. At 24 h after transfection with S p.g of the reporter construct T3RE2-tk-CAT and the indicated amounts of cotransfected c-fos and/or c-jun vectors, cells were transferred to fresh medium supplemented with 5% horse serum and 2.5% fetal calf serum containing 10-7 M T3 or 100 ng of TPA per ml where indicated. Cells were harvested 24 h later, and CAT and 3-gal activities were determined as described in Materials and Methods. (B) Inhibition of endogenous AP-1 activity by endogenous TR. GC cells were grown as described above and transfected with 3 ,ug of -73Col-CAT reporter construct. At 24 h after transfection, cells were transferred to DME supplemented with 0.33% horse serum and 0.17% fetal calf serum with or without TPA (100 ng/ml) or T3 as indicated. CAT and ,-gal activities were determined 24 h later. and ATRP2 were similar, as judged by indirect immunofluorescence microscopy and FACS analysis: approximately 1% of the cells were stained with comparable fluorescence intensities for all constructs. The staining was predominantly in the nucleus.
The carboxy-terminal regions of TRs encode complex functions, including ligand binding, dimerization/oligomerization, and transcriptional activation (16) . It has recently been shown that deletion of carboxy-terminal regions of TR, result in reduced affinity of these proteins for the T3RE as a result of impairment of the dimerization/oligomerization function (73). Zenke et al. (72) showed that a region comparable to that deleted in ATR,1 is essential for transcriptional activation of TRa. The data presented here suggest to us that in addition, this region, either directly or via the dimerization function of the intact receptor, is essential for the anti-AP-1 activity of TR,B. It is interesting that the extreme C-terminal region of c-erbA is deleted in v-erbA (30, 54, 65, 67) . We infer from this that v-erbA is likely to lack the anti-AP-1 activity.
AP-1 but not TRs bind the AP-1 site. Overlapping hormone receptor response elements and AP-1 sites have been reported for several promoters (46, 58 extracts showed strong binding to a T3RE (Fig. 8B) . In vitro-synthesized c-Jun protein and a mixture of c-Jun and c-Fos proteins bound the collagenase promoter as expected (Fig. 7, lanes 2 and 4) , while c-Fos protein alone did not bind to the AP-1 site (Fig. 7, lane 3) . Thus, the repressive effect of TRs is not due to their direct interaction with the collagenase promoter.
Mutual inhibition of AP-1 and TR DNA binding. The mutual inhibition between TRs and c-Jun or c-Fos activity may be due to the mutual interference of these proteins with each other's DNA binding activity. To test this, TRa or TRP proteins were preincubated with c-Jun before addition of labeled AP-1 binding site. We observed a concentrationdependent inhibition of c-Jun DNA binding (Fig. 8A) . To determine the specificity of inhibition, we used a TRa derivative that contained an eight-amino-acid epitope at the amino-terminal end (Flag-TRa) that is recognized by a specific monoclonal antibody (anti-Flag) (25, 27) . The behavior of this TRoa derivative was indistinguishable from that of the wild-type receptor in both transcriptional activation and DNA binding activity (data not shown). When Flag-TRa protein was incubated with c-Jun/c-Fos, a concentrationdependent inhibition of binding to the AP-1 DNA site was observed (Fig. 8A) . For maximum inhibition, an excess amount of TRot was required. The inhibition was specific in that it could be reversed by preincubation of Flag-TRot with the anti-Flag antibody but not by preimmune serum (Fig.  8A) .
Inhibition of c-Jun/c-Fos DNA binding activity by TRs might be due to the formation of a Jun/Fos-TR protein complex, resulting in mutual impairment of DNA binding activity. We therefore investigated the effect of bacterially synthesized c-Jun protein on TR, DNA binding, using the gel shift assay. c-Jun protein inhibited TRP binding to T3RE (11, 46, 58) . We show here, using in vitro DNA binding assays, that TRs and AP-1 can antagonize each other's activity by a mechanism that does not require protein-DNA interaction but rather appears to result from the mutual interference of these proteins with each other's DNA binding activity which may be due to direct protein-protein interaction, as has been suggested by others for the GR/AP-1 (11, 31, 70) and RAR/AP-1 (71) antagonism. The in vitro inhibition of AP-1 DNA binding shown here requires excess amounts of TR, which may suggest that it is a weak interaction. Although direct evidence for protein-protein interaction has been reported in the cases of GR (11, 70) and RAR (71) , other efforts (including our own efforts to show direct TR/AP-1 interaction) have thus far been unsuccessful (57) . These data, together with the cell-type-specific effect of RAR,3 shown in Fig. 2 (34, 53) . Our finding that TRs can interfere with the expression of genes regulated through the signal transduction pathway may therefore represent a major regulatory pathway of TR action. Conversely, TR activity can also be regulated by c-Jun/c-Fos and also by the ras oncogene product (72a) in a manner similar to that observed for GR (26) . The observation of mutual inhibition between TR and the AP-1 complex provides another example that the membrane signaling pathway and nuclear receptor signaling pathway can cross-talk to regulate gene transcription in response to extracellular stimuli. Such interaction might play a crucial role in controlling cell growth and differentiation. AP-1, when stimulated by a number of mitogenic signals, regulates many genes which are involved in cell growth and differentiation (8, 34, 53) . Inhibition of AP-1 activity by the TR-T3 complex can provide cells with a complex control mechanism by which to determine a particular physiological state. The cross-talk between TRs and the signal transduction pathway reported here appears to be a general mechanism that is shared by other nuclear receptors, as was first demonstrated for GR (11, 31, 42, 57, 70) . Recent data from our laboratory and others suggest that RARs can also inhibit AP-1 activity (48, 71) .
Nuclear receptors have so far received limited attention as antioncogenes. However, the data reported here, in combination with recent data on anti-AP-1 activity of GRs and RAR, suggest a prominent role for nuclear receptors as antioncogenes. Not only does AP-1 mediate mitogenic signals, but its deregulated expression also contributes to cellular transformation (39, 43, 59, 60) . The inhibition of AP-1 by TRs might serve as an important regulatory pathway in suppressing in appropriate cellular proliferation initiated by oncoproteins. It is noteworthy that while AP-1 activity can be directly affected by TRs in the presence of TH, we also show that fos promoter activity is downregulated by TRs. Thus, a more pronounced downregulation of AP-1 activity can be achieved and at least one of the AP-1 components, c-Fos, may be completely eliminated. This type of a signal-enhancing mechanism could lead to a major switch in a cell differentiation program. This view i consistent with a recent report showing that ligand-activated TRs and RARs are able to antagonize the activities of cellular erbBl and erbB2 genes (28) .
The ability of TRs to antagonize oncogene activity at various points in the chain of events leading to neoplastic cell proliferation makes it likely that cells in which TRs are downregulated will be more susceptible to growth factor response, tumor promoter, and oncogene activity. Mutation in TRs can therefore increase oncogene effectiveness. A striking example is the v-ErbA protein, which, unlike active TRs, cooperates with a number of oncogenes (17, 32, 33) . It becomes an oncoprotein through mutations that effect its ligand and gene activation functions (9, 55, 72) . Moreover, the extreme C-terminal region of c-ErbA, whi h is required for its anti-AP-1 activity, is deleted in v-ErbA (30, 54, 65, 67) . Since oncogene inhibition by TRs is ligand dependent, v-ErbA and the receptorlike TRa carboxy-terminal variants may not show anti-AP-1 activity, while their reported repressor activity on active receptors (9, 25, 35, 38, 55) may in addition serve to enhance oncogene activities. Furthermore, it will be important to investigate whether TRs or other nuclear receptors that have anti-AP-1 activity are downregulated or mutated in neoplastic cells. In this context, it is of interest to note that many small lung cell tumors carry a deletion in chromosome 3 which may overl, p with the TRO gene (12, 37) .
In conclusion, we have provided evidence for a novel regulatory function of TRs. This function is not mediated by the classical receptor-DNA interaction iut is based on cross-talk between the signal transduction pathway and nuclear TRs. Taken together, our recent findings and those of others (11, 31, 42, 48, 57, 70, 71) suggeqt that this is a general pathway for nuclear receptors. This pathway is not limited to direct c-Jun/c-Fos-receptor antagonism, but may allow the interaction of many oncogenes and growth factors with nuclear receptors through the signal transduction pathway. The interaction of these pathways could provide a 
